GO
Loading...

Abbott Laboratories

More

  • Abbott, Boston Scientific Stents & Stuff Tuesday, 1 Jul 2008 | 10:33 AM ET
    Heart Stent

    So, I can now safely say, with complete confidence, that Food and Drug Administration approval of the new Abbott drug-coated stent will not happen in the second quarter. Recently, at least a couple of analysts have been telling clients a decision was getting pushed out until the third quarter and one suggested that Xience won't be launched until Q4.

  • The Week in Review: Bears on the Prowl Saturday, 28 Jun 2008 | 3:01 PM ET

    By anyone's reckoning, it was a rough week.  Crude oil continued its relentless climb; banks and brokerages gave hints of more discouraging news; government data pointed to a weak economy; even strong companies like Nike, Oracle, and Research In Motion issued cautious guidance; and Federal Reserve policymakers, widely perceived as powerless to help, left interest rates unchanged.  But all week, even through the worst of the market's sell-offs, CNBC guests offered

  • Beaten Down? Snap Them Up, Picker Says Friday, 27 Jun 2008 | 1:28 PM ET

    Where some stock-market investors see losses, Eric Schoenstein sees discounts.  His four-star Jensen Portfolio is up an average of 4.7 percent per year over the last three years, and he's singled out some stocks he finds exceptionally promising and very reasonably priced.

  • Fourth of July fireworks

    FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."

  • Pops & Drops: Abbott Labs, Starbucks... Friday, 16 May 2008 | 6:47 PM ET

    Following are the week’s biggest winners and losers. Find out why shares of Abbott Labs and Starbucks popped while CBS and Dillard's dropped.

  • J&J Stent Ad Under Fire in Medical Journal Wednesday, 14 May 2008 | 5:01 PM ET
    Johnson & Johnson

    Two cardiologists write in "The New England Journal of Medicine" that Johnson and Johnson's first-of-its kind TV commercial for a heart stent is aimed at "millions of people who are ill-equipped to make judgments" about the device.

  • Pops & Drops: Dell, True Religion... Tuesday, 13 May 2008 | 6:38 PM ET

    Following are the day’s biggest winners and losers. Find out why shares of Dell and Fluor popped while True Religion and Western Refining dropped

  • HP Drags on Dow; Yahoo Buoys Nasdaq Tuesday, 13 May 2008 | 5:11 PM ET

    Stocks declined Tuesday as investors expressed their disappointment in Wal-Mart's outlook, HP's deal and a slew of other news. Surprising resilience in retail sales, excluding autos, helped curb losses. The Nasdaq eked out a gain, led by Yahoo.

  • HP Drags on Dow; Icahn Buzz Boosts Yahoo Tuesday, 13 May 2008 | 3:08 PM ET

    Stocks declined Tuesday as investors juggled a mixed bag of news: Retail sales outside of the hard-hit auto sector showed suprising resilience, while a well-known analyst cut her outlook for big banks. Wal-Mart skidded after the discount giant posted decent results but issued a tepid outlook.

  • Study Shows Conflicts in Stent Industry Tuesday, 6 May 2008 | 7:40 PM ET
    Heart Stent

    Too few influential doctors are telling the public if they have financial ties to the companies that make lifesaving drug-coated stents.

  • Merck "Adapts" To Tredaptive Setback Tuesday, 29 Apr 2008 | 11:37 AM ET

    Investors are finding no solace in Merck's reaffirmation that it'll still hit its earnings numbers this year. Instead they're punishing the stock after the company announced what everyone is calling a surprise and a significant setback.

  • Merck Shares Plunge as Cholesterol Drug Rejected Tuesday, 29 Apr 2008 | 11:20 AM ET
    Merck

    U.S. health regulators have rejected a new drug from Merck that was designed to raise the level of HDL, or "good" cholesterol, the company said, sending its shares plunging more than 10 percent.

  • Regulatory "Risky Business" for Pharma & Biotech Monday, 28 Apr 2008 | 11:56 AM ET
    Risky Business

    It's a big day for pipeline progress...or not. Late Friday, Merck and Schering-Plough announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.

  • Wyeth Profit Slips, but Tops Wall Street Estimates Tuesday, 22 Apr 2008 | 7:22 AM ET

    Wyeth Tuesday said its first-quarter net profit fell slightly, hurt by the sudden launch early this year of a generic form of its Protonix ulcer drug, but surprisingly strong sales enabled the company to beat Wall Street profit forecasts.

  • Abbott Profit Rises, Boosted by Prescriptions Wednesday, 16 Apr 2008 | 7:51 AM ET

    Abbott Laboratories said Wednesday first-quarter earnings increased 34 percent on higher sales of its prescription drugs and medical devices and favorable foreign exchange factors.

  • Johnson & Johnson's Earnings And Its Very "Taxing" Day Tuesday, 15 Apr 2008 | 3:56 PM ET
    Johnson & Johnson

    Dow component and healthcare conglomerate (drugs, consumer products, medical devices) Johnson & Johnson beat and boosted. That's Wall Street jargon for earnings coming in higher than expectations and the guidance for the rest of the year being raised. So, why did the stock go down?

  • The Week:  Saving the Worst For Last Saturday, 12 Apr 2008 | 7:31 AM ET
    Stocks down

    A steady stream of downbeat news seemed to leave the market unmoved for most of the week -- until the bluest of the blue chips, General Electric, posted first-quarter earnings that missed Wall Street expectations by seven cents per share, and lowered its full-year guidance.  

  • Week Ahead: Challenging -- At The Least Friday, 11 Apr 2008 | 7:34 PM ET

    A double helping of economic data and first-quarter earnings reports will flood the zone next week, but it's the corporate earnings that will drive stocks and give a better picture of where the economy is going. If GE's bombshell earnings miss is an indicator, the news will be as nasty as traders expect.

  • Japan's Takeda to Buy Millennium Pharma Thursday, 10 Apr 2008 | 6:25 AM ET

    Takeda Pharmaceutical said it would buy U.S. firm Millennium Pharmaceuticals for $8.8 billion to boost its cancer drug business, in the biggest overseas acquisition by a Japanese drug maker.

  • Defensive Stock Picks for a Rebound Monday, 7 Apr 2008 | 1:22 PM ET

    After a rough start, top investment officers are looking for gradual improvement as 2008 goes on.  Harbor Advisory's Jack DeGan is among them, and he won't sugar-coat the current situation.